Anti-Eosinophil-Derived Neurotoxin Antibody, clone 6D1.5/A5

Non-secretory ribonuclease (EC 3.1.27.5; UniProt P10153; also known as Eosinophil-derived neurotoxin, Ribonuclease 2, Ribonuclease US, RNase 2, RNase UpI-2) is encoded by the RNASE2 (also known as EDN, RAF3, RNS2) gene (Gene ID 6036) in human. The major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil derived neurotoxin (EDN) and eosinophil peroxidase (EPO), are eosinophil effector molecules implicated in host defense, immunoregulatory responses, and in allergic and inflammatory reactions. These highly cationic proteins are stored preformed within the eosinophil secondary granules and released in intact membrane-bound granules during cell lysis or through a complex system of vesiculotubular structures during “piecemeal necrosis”. While eosinophil count and eosinophil surface expression of the activation marker CD69 are significantly correlated with serum concentrations of MBP, EDN and EPO, studies show that they are not correlated with ECP level. On the other hand, eosinophilic disease patients with normal eosinophil count show significantly increased concentrations of MBP, ECP, EDN, and EPO compared to normal donors. The measurement of MBP, ECP, EDN, and EPO levels thus provides a better predictor than eosinophil count alone in disease diagnosis. EDN is produced with a signal peptide sequence (a.a. 1-27), the removal of which yields the mature (a.a. 28-161) protein.

Clone 6D1.5/A5 specifically reacted with EDN, but not other granule proteins by Western blotting analysis (Makiya, M.A., et al. (2014). J. Immunol. Methods. 411:11-22).

Purified human EDN.

Anti-Eosinophil-Derived Neurotoxin Antibody, clone 6D1.5/A5 is an antibody against Eosinophil-Derived Neurotoxin for use in Western Blotting, ELISA, Multiplexing.

Research Category
Inflammation & Immunology

Research Sub Category
Inflammation & Autoimmune Mechanisms

Western Blotting Analysis: 1.0 µg/mL from a representative lot detected eosinophil-derived neurotoxin in 50 µg of human liver and lung tissue lysates.
ELISA Analysis: A representative lot was employed as the capture antibody for the detection of purified human EDN, as well as EDN in serum samples from individuals with eosinophilic disorders by sandwich ELISA (Makiya, M.A., et al. (2014). J. Immunol. Methods. 411:11-22),
Multiplexing Analysis: A representative lot was employed as the capture antibody in a bead-based multiplex assay for the detection of purified human EDN as well as EDN in serum samples from healthy donors and individuals with eosinophilic disorders. Prior reduction and alkylation of the serum samples (by DTT and iodoacetamide, respectively) resulted in higher EDN levels (Makiya, M.A., et al. (2014). J. Immunol. Methods. 411:11-22),

Evaluated by Western Blotting in human spleen tissue lysate.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected eosinophil-derived neurotoxin in 50 µg of human spleen tissue lysate.

~20 kDa observed. Target band appears larger than the calculated molecular weights of 18.35 kDa (pro-form) and 15.46 kDa (mature) due to glycosylation. Uncharacterized band(s) may appear in some lysates.

Format: Purified

Protein G Purified

Purified mouse monoclonal IgG1 antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.